These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29549921)

  • 21. Platelet microvesicles in health and disease.
    Melki I; Tessandier N; Zufferey A; Boilard E
    Platelets; 2017 May; 28(3):214-221. PubMed ID: 28102737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis.
    Morel O; Morel N; Jesel L; Freyssinet JM; Toti F
    Semin Immunopathol; 2011 Sep; 33(5):469-86. PubMed ID: 21866419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombosis and hemostatic abnormalities in hematological malignancies.
    Colombo R; Gallipoli P; Castelli R
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):441-50. PubMed ID: 25018062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion.
    Jaiswal R; Johnson MS; Pokharel D; Krishnan SR; Bebawy M
    BMC Cancer; 2017 Feb; 17(1):104. PubMed ID: 28166767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin.
    Cesarman-Maus G; Braggio E; Lome-Maldonado C; Morales-Leyte AL; Fonseca R
    Thromb Res; 2014 Apr; 133(4):606-9. PubMed ID: 24491425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-derived microparticles: new targets in the therapeutic management of disease.
    Roseblade A; Luk F; Rawling T; Ung A; Grau GE; Bebawy M
    J Pharm Pharm Sci; 2013; 16(2):238-53. PubMed ID: 23958193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microparticles and microRNAs: new players in the complex field of coagulation.
    Camaioni C; Gustapane M; Cialdella P; Della Bona R; Biasucci LM
    Intern Emerg Med; 2013 Jun; 8(4):291-6. PubMed ID: 22033788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Membrane microparticles: shedding new light into cancer cell communication.
    de Souza PS; Faccion RS; Bernardo PS; Maia RC
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1395-406. PubMed ID: 26285684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of microparticles in the pathogenesis of rheumatic diseases.
    Beyer C; Pisetsky DS
    Nat Rev Rheumatol; 2010 Jan; 6(1):21-9. PubMed ID: 19949432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microparticle and Atherothrombotic Diseases.
    Nomura S
    J Atheroscler Thromb; 2016; 23(1):1-9. PubMed ID: 26412494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological modulation of microparticle release: new strategies for the management of atherothrombotic vascular disorders.
    Montoro-García S; Orenes-Piñero E; Marín F; Mariano ; Valdés ; Lip GY; Shantsila E
    Curr Pharm Des; 2012; 18(6):840-9. PubMed ID: 22288445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microparticles in cancer.
    Rak J
    Semin Thromb Hemost; 2010 Nov; 36(8):888-906. PubMed ID: 21049390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease.
    Alexandru N; Costa A; Constantin A; Cochior D; Georgescu A
    Curr Stem Cell Res Ther; 2017; 12(2):89-102. PubMed ID: 26647911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection.
    Punyadee N; Mairiang D; Thiemmeca S; Komoltri C; Pan-Ngum W; Chomanee N; Charngkaew K; Tangthawornchaikul N; Limpitikul W; Vasanawathana S; Malasit P; Avirutnan P
    J Virol; 2015 Feb; 89(3):1587-607. PubMed ID: 25410854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microparticles reveal cell activation during IVF - a possible early marker of a prothrombotic state during the first trimester.
    Olausson N; Mobarrez F; Wallen H; Westerlund E; Hovatta O; Henriksson P
    Thromb Haemost; 2016 Aug; 116(3):517-23. PubMed ID: 27412479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating tissue factor-exposing microparticles.
    Lechner D; Weltermann A
    Thromb Res; 2008; 122 Suppl 1():S47-54. PubMed ID: 18691500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.